The Latest Breaking News from Moderna

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma

The long-awaited cancer vaccine revolution is getting a little closer to reality. New data from Moderna Inc. and Merck & Co. suggest that after decades of failures, researchers are finally figuring out the right way to design a vaccine that can teach immune cells how to recognize and combat tumors.

Afrigen is the linchpin of global project to use mRNA technology to empower low-resource countries to make their own vaccines against killer diseases from TB to HIV. What will it take to succeed?

Tesla bounced early after leading a growth sell-off with Moderna and Nvidia. Many industrial and energy plays are thriving

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

Disney weighed on the Dow Jones after Avatar 2 missed box office numbers.

The Dow Jones Industrial Average fell Monday after last week's heavy losses. Tesla stock jumped early on Elon Musk's Twitter poll that said he should step down, but quickly reversed lower.

The market rally came under pressure on a higher Fed rate outlook. Moderna spiked on a cancer vaccine while Tesla continued to dive.

Vertex is the IBD Stock Of The Day. The FDA signed off on its newest study in cystic fibrosis, but VRTX stock is trading sideways.

A world-first melanoma vaccine which personalises treatments for patients may put an end to melanoma as a "death sentence", according to Australian experts.

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma